Risk and management of patients with cancer and heart disease

Loreena Hill; Bruno Delgado; Ekaterini Lambrinou; Tara Mannion; Mark Harbinson; Claire McCune

doi:10.1007/s40119-023-00305-w

Risk and management of patients with cancer and heart disease

Loreena Hill, Bruno Delgado, Ekaterini Lambrinou, Tara Mannion, Mark Harbinson, Claire McCune

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

2 Downloads (Pure)

Abstract

Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient’s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients’ functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

Original language	English
Pages (from-to)	227-241
Number of pages	15
Journal	Cardiology and Therapy
Volume	12
Issue number	2
Early online date	9 Feb 2023
DOIs	https://doi.org/10.1007/s40119-023-00305-w
Publication status	Published (in print/issue) - 1 Jun 2023

Keywords

Anthracycline
Cardiotoxicity
Heart failure
Risk stratification

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40119-023-00305-w

s40119-023-00305-wFinal published version, 831 KBLicence: CC BY-NC

Cite this

@article{ab2af504f1ad446188b49eb3b3e63eae,

title = "Risk and management of patients with cancer and heart disease",

abstract = "Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient{\textquoteright}s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients{\textquoteright} functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.",

keywords = "Anthracycline, Cardiotoxicity, Heart failure, Risk stratification",

author = "Loreena Hill and Bruno Delgado and Ekaterini Lambrinou and Tara Mannion and Mark Harbinson and Claire McCune",

year = "2023",

month = jun,

day = "1",

doi = "10.1007/s40119-023-00305-w",

language = "English",

volume = "12",

pages = "227--241",

journal = "Cardiology and Therapy",

issn = "2193-8261",

publisher = "Adis",

number = "2",

}

TY - JOUR

T1 - Risk and management of patients with cancer and heart disease

AU - Hill, Loreena

AU - Delgado, Bruno

AU - Lambrinou, Ekaterini

AU - Mannion, Tara

AU - Harbinson, Mark

AU - McCune, Claire

PY - 2023/6/1

Y1 - 2023/6/1

N2 - Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient’s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients’ functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

AB - Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient’s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients’ functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

KW - Anthracycline

KW - Cardiotoxicity

KW - Heart failure

KW - Risk stratification

U2 - 10.1007/s40119-023-00305-w

DO - 10.1007/s40119-023-00305-w

M3 - Article

SN - 2193-8261

VL - 12

SP - 227

EP - 241

JO - Cardiology and Therapy

JF - Cardiology and Therapy

IS - 2

ER -

Risk and management of patients with cancer and heart disease

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this